Pfizer reportedly has several bids for its struggling Hospira business, acquired in February of last year, says Bloomberg sources.
News broke in January that Pfizer might be considering a sale, with analysts speculating that selling the devices business would leave Pfizer a more pure-play drugs unit for a possible spinoff.
According to Bloomberg, British engineering firm Smiths Group and German healthcare company Fresenius are among the current bidders. Private equity firm Pamplona Capital Management also made a second-round bid.
Sources say final bids are due by the end of May, for a deal that could be worth about $2 billion.
Read the Bloomberg coverage